Correlates of Achieving Statin Therapy Goals in Children and Adolescents with Dyslipidemia

被引:17
|
作者
Mendelson, Michael M. [1 ,2 ]
Regh, Todd [3 ,7 ]
Chan, James [3 ]
Baker, Annette [1 ]
Ryan, Heather Harker [1 ]
Palumbo, Nicole [1 ]
Johnson, Philip K. [1 ,8 ]
Griggs, Suzanne [1 ]
Boghani, Meera [1 ,4 ]
Desai, Nirav K. [4 ]
Yellen, Elizabeth [1 ,2 ]
Buckley, Lucy [1 ]
Gillman, Matthew W. [1 ,5 ,6 ]
Zachariah, Justin P. [1 ,9 ,10 ]
Graham, Dionne [3 ]
de Ferranti, Sarah D. [1 ]
机构
[1] Boston Childrens Hosp, Dept Cardiol, 300 Longwood Ave, Boston, MA 02115 USA
[2] Boston Univ, Sch Med, Boston, MA 02118 USA
[3] Boston Childrens Hosp, IRCDA, Boston, MA USA
[4] Boston Childrens Hosp, Div Pediat Gastroenterol Hepatol & Nutr, Boston, MA USA
[5] Harvard Med Sch, Dept Populat Med, Boston, MA USA
[6] Harvard Pilgrim Hlth Care, Boston, MA USA
[7] Genzyme, Westborough, MA USA
[8] Albany Med Coll, Albany, NY 12208 USA
[9] Texas Childrens Hosp, Pediat Cardiol Sect, Houston, TX 77030 USA
[10] Baylor Coll Med, Dept Pediat, Houston, TX 77030 USA
来源
JOURNAL OF PEDIATRICS | 2016年 / 178卷
关键词
DENSITY-LIPOPROTEIN-CHOLESTEROL; PROJECT L-TAP; FAMILIAL HYPERCHOLESTEROLEMIA; LIPID-LEVELS; FOLLOW-UP; PREVALENCE; EFFICACY; PLASMA; RISK;
D O I
10.1016/j.jpeds.2016.08.003
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Objective To determine the real-world effectiveness of statins and impact of baseline factors on low-density lipoprotein cholesterol (LDL-C) reduction among children and adolescents. Study design We analyzed data prospectively collected from a quality improvement initiative in the Boston Children's Hospital Preventive Cardiology Program. We included patients <= 21 years of age initiated on statins between September 2010 and March 2014. The primary outcome was first achieving goal LDL-C, defined as < 130 mg/dL, or < 100 mg/dL with high-level risk factors (eg, diabetes, etc). Cox proportional hazards models were used to assess the impact of baseline clinical and lifestyle factors. Results Among the 1521 pediatric patients evaluated in 3813 clinical encounters over 3.5 years, 97 patients (6.3%) were started on statin therapy and had follow-up data (median age 14 [IQR 7] years, 54% were female, and 24% obese, 62% with at least one lifestyle risk factor). The median baseline LDL-C was 215 (IQR 78) mg/dL, and median follow-up after starting statin was 1 (IQR 1.3) year. The cumulative probability of achieving LDL-C goal within 1 year was 60% (95% CI 47-69). A lower probability of achieving LDL-C goals was associated with male sex (HR 0.5 [95% CI 0.3-0.8]) and higher baseline LDL-C (HR 0.92 [95% CI 0.87-0.98] per 10 mg/dL), but not age, body mass index percentile, lifestyle factors, or family history. Conclusions The majority of pediatric patients started on statins reached LDL-C treatment goals within 1 year. Male patients and those with greater baseline LDL-C were less likely to be successful and may require increased support.
引用
收藏
页码:149 / +
页数:16
相关论文
共 50 条
  • [41] Importance of Dyslipidemia Screening in Children and Adolescents Reply
    Schefft, Matthew
    Schroeder, Alan R.
    Quinonez, Ricardo
    AMERICAN FAMILY PHYSICIAN, 2019, 100 (07) : 392 - 392
  • [42] PLANNING INSULIN THERAPY AND ITS GOALS IN CHILDREN AND ADOLESCENTS WITH DIABETES-MELLITUS
    BURGER, W
    ERNAHRUNGS UMSCHAU, 1991, 38 (06): : 246 - 246
  • [43] Correlates of adiponectin in children and adolescents
    Diamond, FB
    Cuthbertson, DD
    Eichler, DC
    PEDIATRIC RESEARCH, 2003, 53 (04) : 169A - 169A
  • [44] Achieving target cholesterol goals after stroke - Is in-hospital statin initiation the key?
    Sanossian, Nerses
    Saver, Jeffrey L.
    Liebeskind, David S.
    Kim, Doojim
    Razinia, Tannaz
    Ovbiagele, Bruce
    ARCHIVES OF NEUROLOGY, 2006, 63 (08) : 1081 - 1083
  • [45] Risk factors associated with atherogenic dyslipidemia in the presence of optimal statin therapy
    Zhao, Wang
    Zheng, Xi-Long
    Jiang, Ze-Nan
    Liao, Xiao-Bo
    Zhao, Shui-Ping
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 248 : 355 - 360
  • [46] Is it necessary to add fibrate to statin therapy in the management of dyslipidemia of metabolic syndrome?
    Turhan, Hasan
    Yetkin, Ertan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2006, 110 (02) : 276 - 277
  • [47] Intensity of statin therapy and primary prevention of cardiovascular in Korean patients with dyslipidemia
    Song, Sun Ok
    Kang, Min Jin
    Suh, Sunghwan
    MEDICINE, 2024, 103 (11) : E37536
  • [48] Fenofibric acid plus statin combination therapy for the treatment of mixed dyslipidemia
    Jones, Peter H.
    CLINICAL LIPIDOLOGY, 2009, 4 (06) : 699 - 711
  • [49] MACHINE LEARNING-BASED PERSONALIZED STATIN THERAPY FOR DYSLIPIDEMIA MANAGEMENT
    Joo, Hyung Joon
    Kim, Eung Ju
    Kim, Yong H.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2024, 83 (13) : 1716 - 1716
  • [50] Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
    Lee, Jeongmin
    Lee, Seung-Hwan
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2023, 38 (06): : 797 - 809